Cargando…
Double-hit and double-expressor primary central nervous system lymphoma: Experience from North India of an infrequent but aggressive variant
BACKGROUND: High-grade non-Hodgkin B-cell lymphoma is an aggressive mature B-cell lymphoma that depicts poor treatment response and worse prognosis. The presence of MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements qualifies for triple-hit and double-hit lymphomas (THL/...
Autores principales: | Parkhi, Mayur, Chatterjee, Debajyoti, Radotra, Bishan Dass, Bal, Amanjit, Yadav, Budhi Singh, Tripathi, Manjul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Scientific Scholar
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246369/ https://www.ncbi.nlm.nih.gov/pubmed/37292392 http://dx.doi.org/10.25259/SNI_307_2023 |
Ejemplares similares
-
Clinicopathological features of primary central nervous system diffuse large B cell lymphoma: Experience from a Tertiary Center in North India
por: Radotra, Bishan Dass, et al.
Publicado: (2020) -
Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility
por: Craig, Jeffrey W., et al.
Publicado: (2018) -
Primary Cutaneous Diffuse Large B-Cell Lymphoma of the Upper Limb: Double Hit/Double Expressor with CNS Involvement: From Hospice to Remission
por: Castillo, Brenda S., et al.
Publicado: (2019) -
Treatment Outcomes and Clinical Relevance in Patients with Double Expressor DLBCL
por: Rungwittayatiwat, Sirapat, et al.
Publicado: (2021) -
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome
por: Dodero, Anna, et al.
Publicado: (2021)